A September ESHRE Campus workshop organised by the SIGs Fertility Preservation and Stem Cells featured current and emerging approaches for fertility preservation, including oocyte in vitro maturation, cell therapy, reproductive tissue engineering and organ-on-chip approaches. Mina Popovic and Christiani Amorim from the SIG Stem Cells report from the two-day programme.
Fertility preservation is a highly imperative, in-demand service aimed at improving the quality of life for individuals at high risk of infertility. Originally applied in oncological patients requiring gonadotoxic therapies, strategies have now rapidly expanded to other populations. Nevertheless, many patients still lack safe and efficient treatment opportunities.
In the opening lecture, Kirsten Macklon, Past Co-ordinator of the SIG Fertility Preservation, emphasised the risks of cancer, chemo- and radiation therapy on fertility. She further outlined current options for fertility preservation, including the cryopreservation of gametes, embryos and reproductive tissues. However, as she explained, timing, suitability and safety remain a significant challenge. Accordingly, fertility preservation technologies remain largely experimental in prepubertal children, patients requiring urgent cancer treatment and those for whom ovarian stimulation is contraindicated or unfeasible.
Professor Michal Grynberg, current Co-ordinator of the SIG, discussed his clinical experience with oocyte IVM. He highlighted the benefits of this strategy for restoring fertility in different patient populations, including young women with breast cancer and haematological conditions. He further reported on the first successful application of IVM in a patient with autoimmune premature ovarian insufficiency, performed by his group.(1) Thus far, oocyte donation has been the only available treatment for women presenting with this condition, as severe follicular loss and markedly elevated FSH levels preclude ovarian stimulation.
Antonio Pellicer presented an alternative strategy for treating women with POI and diminished ovarian reserve known as autologous stem cell ovarian transplantation (ASCOT). Pioneered by his group at IVIRMA, this method infuses bone marrow-derived stem cells into the ovarian artery.(2) Pellicer explained that stem cell-secreted factors may increase reproductive potential by promoting ovarian vascularisation, cell proliferation, and reducing apoptosis. After promising results in animal models and low-responder patients, the ASCOT technique is now being evaluated in patients with POI as part of a clinical trial (NCT04475744).
Ovarian function may also be restored through cell-based hormone replacement therapy, an approach emerging from regenerative medicine. Emmanuel Operas group at Wake Forest University, North Carolina, is currently developing this method as a potential therapy for prolonged estrogen deficiency, as seen in women with premature ovarian failure and menopause. By encapsulating granulosa and theca cells in hydrogel constructs, the group bioengineered a 3D ovarian endocrine unit that mimics the spatial arrangement of follicular cells in the ovary.(3) Following implantation in ovariectomised rats, the constructs achieved stable secretion of hormones. Moreover, the constructs were effective in improving adverse effects of hormone deficiency, including bone and uterine health and body composition in the rat model.
Another promising strategy at the crossroads of regenerative and reproductive medicine is reproductive tissue engineering. This newly emerging field aims to construct reproductive tissues and organs in vitro. Lisa White from the University of Nottingham, UK, explained that the success of this approach will ultimately rely on generating the right culture conditions. She described how various biomaterials have been applied to replicate the architecture, mechanical properies and stimulatory factors of different tissues, pointing out that creating a cell-responsive environment remains the greatest challenge. White revealed that utilising the extracellular matrix (ECM) as a scaffold for tissue engineering may be the solution. She reported that ECM scaffolds can be synthesised through the process of decellularisation or used to generate hydrogels, a more flexible culture matrix. Nevertheless, both processes require extensive optimisation for each tissue. We must deconstruct in order to reconstruct, she said, stressing that understanding reproductive tissues will be critical for future reproductive tissue engineering efforts.
Christiani Amorim and her group at UC Louvain, Belgium, have indeed adopted this approach. By deconstructing the human ovary, she revealed that changes in the rigidity of the ovarian ECM can have a direct effect on the behaviour of follicles. She presented her groups latest findings on the ultrastructure of ovarian tissues from prepuberty to menopause.(4) Close examination of ovarian tissue samples across different ages revealed higher collagen and lower elastin levels in ECMs surrounding prepubertal follicles than in those obtained from reproductive-age and menopausal women. Such a stiff niche points to high levels of mechanical stress, leading to a nonpermissive environment for prepubertal follicle activation and growth. These factors will be important to consider when constructing ECM scaffolds for ovarian tissue engineering.
Irene Cervell from IVIRMA presented an overview of uterine tissue engineering. She shared her experience with decellularised endometrial matrices and decellularised endometrial hydrogels, describing promising results of these approaches for repairing the endometrium in an animal model. Hydrogels generated from decellularised pig endometrium were further used by her group to improve current human endometrial organoid culture systems.(5) Although 3D endometrial organoids provide advantages over traditional 2D culture methodologies, they lack stromal cells and thus cannot recapitulate reciprocal cell interactions underlying proliferation, differentiation and decidualisation. Cervell said that allowing the endometrial epithelial cells to interact with soluble ECM tissue-specific molecules provided a more favourable system for culturing endometrial organoids.
This Campus meeting also examined new research into male fertility preservation. Several promising techniques were considered, including in vitro spermatogenesis, the development of ex vivo and in vitro systems to generate functional testicular organoids, as well as microfluidic chips for the maintenance of testicular tissue. Stefan Schlatt from the University of Munster and a former Co-ordinator of the SIG Andrology gave a timely update on these state-of-the-art technologies. He explained that extensive efforts have been made in recapitulating the process of male gametogenesis in vitro; however, success will rely on understanding human germ line segregation, germ cell plasticity, soma-germline interactions and the spermatogonial stem-cell (SSC) niche. All of these processes still remain unclear, he said. A promising technology to bridge this research gap is organ-on-chip technology. Schlatts group has applied this system to maintain human, monkey and rodent seminiferous tubules, a step forward in understanding the testis microenvironment.(6)
Ans van Pelt from AMC Amsterdam described potential options for restoring fertility in men from cryopreserved testicular tissue. Male cancer survivors are greatly predisposed to infertility because of the high sensitivity of SSCs to damage. This is especially devastating for prepubertal patients who cannot benefit from sperm cryopreservation. Although mature functional sperm cells are absent in young boys, a functional pool of SSCs is present from birth. Accordingly, propagation of SSCs from testicular tissue and subsequent transplantation into the testis has been suggested as a novel fertility restoration approach for infertile male cancer survivors. Van Pelt explained that this method has been successfully applied in the mouse model, although the in vitro propagation of human spermatogonia has proven challenging.(7) A major limitation is endogenous somatic testicular cell overgrowth during long-term culture. Nevertheless, this system has been valuable for unravelling the transcriptomic signature of several testicular cell types, an important step forward towards understanding human spermatogenesis.
Jan-Bernd Stukenborg from the Karolinska Institute in Stockholm discussed an alternative option, testicular tissue engineering. He highlighted the promise of organoid formation assays for studying spermatogenic events in detail. He described a 3D multilayer model developed by his group which allows the formation of rat testicular organoids with a functional blood-testis barrier.(8) These testicular organoids were composed of Sertoli cells and proliferating germ cells organised in spherical-tubular structures. Stukenborgs group is currently evaluating this system in humans. He explained that testicular organoids may provide a simpler and more efficient means to identify unknown factors responsible for SSC propagation and differentiation.
While science makes progress, the meeting also stressed the importance of awareness and greater access to fertility preservation treatments. Mary Wingfield from Dublin thus emphasised the need for more comprehensive, standardised and accessible fertility preservation programmes. She revealed the alarming variation in the availability and accessibility of fertility preservation services across Europe, especially for paediatric patients and as an example described the Childhood Cancer Fertility Project in Ireland. This initiative offers free gamete preservation to young adults before gonadotoxic cancer treatment and works to develop new methods to preserve fertility in children with cancer. She concluded her talk with the resonating message that all children, adolescents and adults at risk of infertility deserve a service that is safe, comprehensive and accessible. As reflected in this ESHRE Campus, achieving such a goal will ultimately rely on a collaborative, multidisciplinary approach. Certainly, much can be gained at this valuable crossroads of science, technology and medicine.
1. Grynberg M, Jacquesson L, Sifer C. In vitro maturation of oocytes for preserving fertility in autoimmune premature ovarian insufficiency. Fertil Steril 2020; 114, 848853.doi: 10.1016/j.fertnstert.2020.04.049
2. Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril 2018; 110: 496-505.e1.doi:10.1016/j.fertnstert.2018.04.025.
3. Sittadjody S, Saul JM, McQuilling JP, et al. In vivo transplantation of 3D encapsulated ovarian constructs in rats corrects abnormalities of ovarian failure. Nat Commun 2017; 8: 1858. doi: 10.1038/s41467-017-01851-3
4. Ouni E, Bouzin C, Dolmans MM, et al. Spatiotemporal changes in mechanical matrisome components of the human ovary from prepuberty to menopause. Hum Reprod 2020; 35: 13911410. doi: 10.1093/humrep/deaa100.
5. Francs-Herrero E, Jurez-Barber E, Campo H, et al. Improved models of human endometrial organoids based on hydrogels from decellularized endometrium. J Pers Med 2021; 11: 504. doi: 10.3390/jpm11060504
6. Sharma S, Venzac B, Burgers T, et al. Microfluidics in male reproduction: is ex vivo culture of primate testis tissue a future strategy for ART or toxicology research? Mol Hum Reprod 2020; 26: 179192.doi:10.1093/molehr/gaaa006
7. Struijk RB, Mulder CL, van Daalen SKM, et al. ITGA6+ human testicular cell populations acquire a mesenchymal rather than germ cell transcriptional signature during long-term culture. Int J Mol Sci 2020; 21:8269. doi:10.3390/ijms21218269
8. Alves-Lopes JP, Sder O, Stukenborg JB. Testicular organoid generation by a novel in vitro three-layer gradient system. Biomaterials 2017; 130: 76-89.doi:10.1016/j.biomaterials.2017.03.025
reproductive tissue engineeringovarian functionregenerative medicinefertility preservation
Read this article:
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021
- Shifts Away From R-CHOP Treatment Shows Improved EFS and OS Benefit in MCL - Targeted Oncology - September 25th, 2021